Table 2.
Patient characteristics
| Variable | No. of Patients (%) |
|---|---|
| No. of patients | 107 (100) |
| Age: Median [range], y | 50.15 (17–88) |
| Gender | |
| Male | 86 (80.37) |
| Female | 21 (19.63) |
| HBsAg status | |
| Negative | 17 (15.88) |
| Positive | 90 (84.12) |
| Child‐Pugh class | |
| A | 101 (94.39) |
| B | 6 (5.61) |
| AFP: Median [range], ng/mL | 4465.2 (0–217,935) |
| Tumor size: Median [range], cm | 4.29 (0.90–12.80) |
| Liver cirrhosis | |
| Absent | 40 (37.38) |
| Present | 67 (62.62) |
| ALT: Median [range], U/L | 35.98 (5–245) |
| Tumor multiplicity | |
| Solitary | 100 (93.46) |
| Multiple | 7 (6.54) |
| Vascular invasion | |
| Absent | 99 (92.52) |
| Present | 8 (7.48) |
| Metastasis | |
| Absent | 98 (91.59) |
| Present | 9 (8.41) |
| BCLC stage | |
| 0 | 15 (14.02) |
| A | 89 (83.18) |
| B | 2 (1.87) |
| C | 1 (0.93) |
| Recurrence | |
| pNrf2 | |
| high | 38 (50.67) |
| low | 10 (31.25) |
| Keap1 | |
| reduced | 24 (50.00) |
| preserved | 21 (35.60) |
HBsAg, hepatitis B surface antigen; AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer.